Alnylam May Not Reach Partnership Goal for ‘09, Partner Cubist to Focus on Follow-On RSV Rx

As its search for at least two new major industry partners potentially extends into next year, Alnylam said that Cubist has decided to focus its attention on a second-generation molecule rather than the RSV program’s original drug candidate.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.